2 not yet recruiting, 1 completed. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Silymarin 420 mg: new trials by email Literature Review of Silymarin 420 mg trials Research Report on Silymarin 420 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vitamin E Versus Silymarin in Non Diabetic MASLD Patients Vitamin E 800 IU/d, Silymarin 420 mg, Placebo - Metabolic Dysfunction-Associated Steatoic Liver Disease | Phase 3 | Not yet recruiting | Kafrelsheikh University | 120 | 2026-10-16 | 2026-10-13 |
| Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi Silymarin 420 mg, N Acetyl Cysteine, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) - Drug Induced Liver Injury, Tuberculosis (TB) | Phase 1 | Not yet recruiting | Liaquat National Hospital & Medical College | 410 | 2025-07-01 | 2025-07-10 |
| Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Placebo, Silymarin 700 mg, Silymarin 420 mg - Non-alcoholic Steatohepatitis | Phase 2 | Completed | Madaus Inc | 78 | 2008-04-01 | 2019-07-17 |
Chemical and Drug Induced Liver Injury (1) · Non-alcoholic Fatty Liver Disease (1) · Tuberculosis (1)
Kafrelsheikh University (1) · Liaquat National Hospital & Medical College (1) · Madaus Inc (1)
Egypt (1) · United States (1)
Ariba Sultan (1) · K. Rajender Reddy, MD (1) · Michael Fried, MD (1) · Nezam Afdhal, MD (1) · Stephen A. Harrison, MD (1) · Steven H. Belle, PhD (1) · Victor Navarro, MD (1)